What Is Kratom Powder? Everything You Should Know Before Using It

What Is the Kratom Plant?

Kratom (Mitragyna speciosa Korth.) is a tropical evergreen tree in the family Rubiaceae — the same botanical family as coffee (Coffea spp.) and gardenia. Native to the humid lowlands of Southeast Asia, it grows primarily in Indonesia, Malaysia, Thailand, and Myanmar. Mature trees reach 10–25 meters (33–82 feet) in height, with broad, dark green ovate leaves typically 14–20 cm long. The leaves are the commercially relevant part — they are harvested, dried, and processed into the powders, capsules, teas, and extracts sold in Western markets.

The coffee family connection is more than taxonomic — both kratom and coffee produce stimulant effects at lower doses through related alkaloid mechanisms, and both have long histories of use by working populations seeking energy and focus. Kratom’s alkaloid profile is far more complex than caffeine, however, and includes opioid receptor activity that coffee does not share.

What Is Kratom’s History of Use?

Kratom’s traditional use in Southeast Asia predates Western documentation by centuries. Thai and Malaysian agricultural workers chewed fresh kratom leaves to manage fatigue during long work days, reduce musculoskeletal pain, and improve mood — in much the same way coca leaves have been used in South America. Suwanlert (1975) documented that kratom was so prevalent in southern Thailand that some estimates suggested up to 70% of the male population in certain provinces used it regularly.

The earliest formal Western botanical description came from Dutch colonial botanist Pieter Korthals in 1839. The first detailed pharmacological account followed decades later, and mitragynine — kratom’s primary alkaloid — was first isolated in 1921. Its complete chemical structure was not fully determined until 1964.

In Thailand, kratom was placed under the Kratom Act in 1943 and remained controlled for decades — partly due to competition with the government-run opium trade and partly due to anti-drug campaigns that classified it alongside heroin and cocaine. Thailand reversed course in 2021, legalizing kratom and removing it from the narcotics list, recognizing its long cultural history and limited harm profile relative to other controlled substances.

In the United States, kratom use grew substantially in the 2000s and 2010s. The DEA considered emergency scheduling in 2016 but withdrew the proposal following significant public and scientific pushback. The Grundmann (2017) national user survey documented the scope and demographics of kratom use across the US at scale.^[4] The American Kratom Association now estimates 10–16 million regular users in the US. The World Health Organization’s Expert Committee on Drug Dependence reviewed kratom in 2021 and decided against recommending international scheduling.

What Alkaloids Does Kratom Contain?

Kratom leaf contains more than 40 pharmacologically active compounds. The two most studied and clinically relevant are mitragynine and 7-hydroxymitragynine, but the broader alkaloid matrix contributes to the overall pharmacological profile in ways that are still being characterized.

Mitragynine — The dominant alkaloid, typically comprising 60–66% of the total alkaloid fraction in commercial kratom. It is an indole alkaloid structurally distinct from classical opioids (morphine, codeine) but acts as a partial agonist at mu-opioid receptors. It also interacts with adrenergic, serotonergic (5-HT2A), and dopaminergic receptor systems, which explains the stimulant effects at low doses. Kruegel et al. (2018) characterized mitragynine as a “biased agonist” — activating opioid receptors through G-protein signaling pathways while showing reduced recruitment of beta-arrestin-2 compared to classical opioids.^[1]

7-Hydroxymitragynine (7-HMG) — A minor alkaloid present at approximately 2% of the total alkaloid fraction in whole-leaf kratom, but significantly more potent at the mu-opioid receptor than mitragynine. Despite its low concentration, 7-HMG is believed to contribute substantially to kratom’s analgesic effects at higher doses. Products that artificially concentrate 7-HMG (isolated 7-OH products) raise distinct safety concerns that do not apply to whole-leaf kratom in the same way.

Other alkaloids — Speciogynine, paynantheine, speciociliatine, and corynantheidine, among others, contribute to the overall alkaloid matrix. Their individual pharmacologies are less well characterized but may contribute to kratom’s unusual receptor profile and the differences between vein colors.

How Does Kratom Work in the Body?

Prozialeck et al. (2012) reviewed kratom’s pharmacological mechanisms and established the framework that most subsequent research has built on: kratom produces dose-dependent biphasic effects through activity at multiple receptor systems, with the balance shifting from adrenergic to opioid-receptor-dominant as dose increases.^[2]

At low doses (1–4g of plain leaf powder), adrenergic receptor stimulation predominates — producing increased energy, alertness, and focus. This mechanism is more similar to a stimulant than an opioid at this dose range. At high doses (5g+), mu-opioid receptor activation becomes dominant — producing sedation, analgesia, and the subjective effects more typically associated with opioid-class compounds.

The key pharmacokinetic parameters, established by Trakulsrichai et al. (2015) in a controlled human study, include: time to peak plasma concentration (Tmax) of approximately 1.5 hours after oral ingestion; elimination half-life of approximately 9 hours; and substantial individual variation in plasma levels at equivalent oral doses due to CYP3A4 and CYP2D6 enzyme variation.^[3]

Kratom’s biased agonism at the mu-opioid receptor — activating G-protein signaling while showing reduced beta-arrestin-2 recruitment — has attracted pharmaceutical research interest.^[1] This pharmacological profile as a potential framework for safer analgesic development. This profile theoretically reduces the respiratory depression risk associated with classical opioids, though clinical confirmation in humans is still limited.

What Effects Does Kratom Produce?

Grundmann (2017) surveyed 8,049 US kratom users and documented the most commonly reported reasons for use and effects experienced — providing the largest systematic dataset of kratom effects in a real-world population.^[4] Swogger et al. (2015) conducted qualitative interviews documenting first-person accounts of how kratom users describe the experience.^[5]

The most commonly reported effects, organized by dose range:

• Low doses (1–4g): Increased energy and alertness; elevated mood; enhanced sociability and verbal ease; improved focus and motivation; mild euphoria
• Moderate doses (3–6g): Relaxation; anxiety reduction; moderate analgesia; warm physical sensation
• High doses (5g+): Strong sedation; significant pain relief; reduced mental clarity; heavy physical relaxation

Effects duration is approximately 3–6 hours at moderate doses, with peak plasma levels around 1.5 hours post-ingestion. Vein color — white, green, red — shifts the character of effects within this framework, with white vein more stimulant-dominant and red vein more sedative/analgesic-dominant. For the full effects mechanism and dose-dependent breakdown, see our Kratom Effects Overview.

What Forms Is Kratom Available In?

Commercial kratom is sold in several formats, each with different onset timing, dose control characteristics, and practical trade-offs:

• Kratom powder — ground dried leaf, the most common and versatile form. Allows precise dosing with a digital scale. Onset 15–30 min on empty stomach.
• Kratom capsules — pre-measured powder in gelatin or vegetable capsules. Tasteless, convenient. Onset 30–60 min due to capsule dissolution time.
• Kratom tea — powder or crushed leaf steeped in hot water, traditionally with lemon or lime. Onset 20–40 min; slightly lower alkaloid yield than consuming full powder.
• Kratom extracts — concentrated alkaloid preparations. Significantly more potent gram-for-gram than plain leaf; not dose-equivalent. Not recommended for new users.
• Kratom shots — liquid extract format; fastest commercial onset (10–25 min). Fixed dose per bottle.
• Kratom gummies — extract in edible form; pre-dosed per piece.

For a complete consumption guide including how to use each form, see our How to Use Kratom guide. For dosing across formats, see our Kratom Dosage Guide.

Is Kratom Legal?

As of April 2026, kratom is not a federally controlled substance under the US Controlled Substances Act. It is sold legally at the federal level. However, state and local regulations vary significantly:

• States where kratom is banned or heavily restricted: Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin (state-level bans as of 2026)
• States with Kratom Consumer Protection Act (KCPA): Several states have enacted KCPA legislation establishing age restrictions, labeling requirements, and GMP standards without banning kratom
• Federal status: The DEA considered emergency scheduling in 2016 but withdrew the proposal after public comment. Kratom remains unscheduled federally.
• FDA status: Not approved for any medical use. The FDA has issued import alerts and enforcement actions against specific kratom products making drug claims or found with adulterants.

For state-by-state detail and current regulatory updates, see our Kratom Legality Guide.

Is Kratom Safe?

Kratom’s safety profile is complex and dose-dependent. Smith et al. (2022) documented that adverse effects in user populations are most commonly associated with higher doses and daily use frequency — consistent with the known opioid receptor mechanism.^[6]

Established risks:

• Dependence — Daily use produces mu-opioid receptor downregulation and physical dependence in a meaningful proportion of users. Discontinuation symptoms (insomnia, irritability, muscle aches, anxiety) are documented in chronic daily users.
• CYP enzyme inhibition — Mitragynine inhibits CYP3A4 and CYP2D6, creating drug interaction potential with many prescription medications.
• Dose-dependent side effects — nausea, constipation, dizziness, and cognitive dulling at higher doses.
• Quality variation — Without FDA oversight, product alkaloid content varies; COA-verified products reduce this risk.

Kratom is not associated with the level of respiratory depression risk that classical opioids carry, due to its partial agonism and biased signaling profile. Deaths attributed to kratom alone (without other substances) are extremely rare and involve disputed circumstances. Most kratom-associated fatalities involve concurrent use of other central nervous system depressants.

Responsible use principles: start at the lowest effective dose, avoid daily use when possible, monitor for tolerance development, and consult a healthcare provider if you take prescription medications. For the full safety analysis, see our Kratom Side Effects Guide.

Frequently Asked Questions

Is kratom an opioid?

Kratom is not a classical opioid, but its primary alkaloid mitragynine does act as a partial agonist at mu-opioid receptors — the same receptors targeted by morphine, codeine, and other opioid drugs. This is a meaningful pharmacological overlap: it explains kratom’s analgesic properties, its dependence potential with chronic use, and why some clinicians and regulators categorize it similarly to opioids. However, kratom’s biased signaling profile (reduced beta-arrestin-2 recruitment) and complex multi-receptor pharmacology distinguish it from classical opioids in important ways.

What is the difference between white, green, and red vein kratom?

Vein color refers to the color of the leaf’s central vein at time of harvest, and reflects the alkaloid profile of the leaf at different maturity stages. White vein (young leaves) is more stimulant-dominant — higher energy, sharper focus, faster onset. Red vein (mature leaves, often dried longer) is more sedative/analgesic-dominant — relaxation, pain relief, longer duration. Green vein is the balanced middle — moderate stimulation at lower doses, relaxation during taper. Processing method also alters alkaloid ratios, which is why yellow and gold vein kratom exist as processing variants. For the full alkaloid science, see our Kratom Strains Guide.

Is kratom addictive?

Daily kratom use can produce physical dependence — specifically, mu-opioid receptor downregulation that leads to withdrawal symptoms when the compound is withheld. This is the mechanism underlying “addiction” in the pharmacological sense. Whether any individual user develops problematic addictive behavior (compulsive use despite harm) depends on factors beyond pharmacology. The risk is dose-dependent and frequency-dependent: occasional use carries minimal dependence risk; daily high-dose use carries meaningful risk. Kratom’s dependence potential is considered lower than classical opioids but should not be dismissed.

What does kratom look like?

Commercial kratom powder is a fine, somewhat fibrous powder ranging from light green to dark brown depending on vein color and processing. White vein powder tends toward lighter, more yellow-green tones; red vein powder is typically darker brown-green. The smell is earthy and somewhat grassy with a slight bitterness. Capsules are the same powder in a clear, green, or white gelatin or vegetable capsule shell.

Can you drink kratom as a tea?

Yes — kratom tea is one of the oldest and most traditional preparation methods. Kratom leaves or powder are simmered in water (often with lemon juice to improve alkaloid extraction), strained, and consumed as a beverage. The onset is slightly slower and smoother than toss-and-wash powder, and many users report better stomach tolerance with tea. See our complete Kratom Tea Guide.

How is kratom different from CBD?

Kratom and CBD are both plant-derived wellness compounds, but they work through completely different receptor systems. Kratom acts primarily on opioid and adrenergic receptors; CBD acts on the endocannabinoid system and serotonin receptors. They produce different effect profiles and carry different risk profiles — kratom has higher dependence potential due to opioid receptor activity, while CBD has stronger evidence for anxiety specifically. See our full comparison: Kratom vs. CBD.

Where does the kratom sold in the US come from?

Nearly all commercial kratom sold in the US is grown in Indonesia — primarily in Kalimantan (Indonesian Borneo), Sumatra, and Sulawesi. It is harvested, dried, ground, and exported as leaf or powder. Most US vendors source from Indonesian suppliers, with quality varying substantially based on sourcing relationships, drying methods, and alkaloid testing. At Amazing Botanicals, every batch is third-party lab tested for alkaloid content and contaminants — COAs are published at our lab testing page.

Related Guides

References

1. Kruegel AC, Uprety R, Grinnell SG et al. (2018). 7-Hydroxymitragynine Is an Active Metabolite of Mitragynine and a Key Mediator of Its Analgesic Effects. ACS Central Science. [PubMed]
2. Prozialeck WC, Jivan JK, Andurkar SV. (2012). Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. Journal of the American Osteopathic Association. [PubMed]
3. Trakulsrichai S, Sathirakul K, Auparppong S et al. (2015). Pharmacokinetics of mitragynine in man. Drug Design, Development and Therapy. [PubMed]
4. Grundmann O. (2017). Patterns of kratom use and health impact in the US — results from an online survey. Drug and Alcohol Dependence. [PubMed]
5. Swogger MT, Hart E, Erowid F et al. (2015). Experiences of kratom users: a qualitative analysis. Journal of Psychoactive Drugs. [PubMed]
6. Smith KE, Feldman AZ, Rogers JM et al. (2022). Searching for a signal: self-reported kratom dose-effect relationships among a sample of US adults with regular kratom use histories. Drug and Alcohol Dependence. [PubMed]